Cerebrospinal fluid tau and Aβ42 as predictors of development of Alzheimer's disease in patients with mild cognitive impairment

被引：209

作者：

Andreasen, N

Minthon, L

Vanmechelen, E

Vanderstichele, H

Davidsson, P

Winblad, B

Blennow, K

机构：

[1] Pitea River Valley Hosp, Dept Rehabil, SE-94128 Pitea, Sweden

[2] Lund Univ, Malmo Univ Hosp, Dept Community Med, Neuropsychiat Clin, SE-20502 Malmo, Sweden

[3] Innogenetics, B-9052 Ghent, Belgium

[4] Univ Gothenburg, Sahlgrens Univ Hosp, Dept Clin Neurosci, Sect Expt Neurosci, SE-43180 Molndal, Sweden

[5] Huddinge Univ Hosp, Karolinska Inst, Dept Clin Neurosci & Family Med, Geriatr Med Sect, SE-14186 Huddinge, Sweden

[6] MRC, Stockholm, Sweden

来源：

NEUROSCIENCE LETTERS | 1999年 / 273卷 / 01期

关键词：

Alzheimer's disease; beta-amyloid; biochemical markers; cerebrospinal fluid; sensitivity; tau;

D O I：

10.1016/S0304-3940(99)00617-5

中图分类号：

Q189 [神经科学];

学科分类号：

071006 ;

摘要：

We studied CSF-tau and CSF-A beta 42 in 16 patients with mild cognitive impairment (MC[) who at follow-up investigations 6-27 months later had progressed to Alzheimer's disease (AD) with dementia. For comparison, we studied 15 age-matched healthy individuals. At baseline, 14/16 (88%) of MCI patients had high CSF-tau and/or low CSF-A beta 42 levels. These findings show that these CSF-markers are abnormal before the onset of clinical dementia and that they may help to identify MCI patients that will develop AD. This is especially important when drugs with potential effects on the progression of AD will reach the clinical phase. (C) 1999 Elsevier Science Ireland Ltd. All rights reserved.

引用

页码：5 / 8

页数：4